

# David Drobne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8490398/publications.pdf>

Version: 2024-02-01

6  
papers

139  
citations

1477746

6  
h-index

1872312

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

210  
citing authors

#	ARTICLE	IF	CITATIONS
1	Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 111-118.e10.	2.4	28
2	Dose optimisation for Loss of Response to Vedolizumab's Pharmacokinetics and Immune Mechanisms. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1707-1719.	0.6	16
3	Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. <i>Pharmaceutics</i> , 2021, 13, 1587.	2.0	8
4	Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 741-749.	1.6	17
5	Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 880-889.	1.9	32
6	Success and safety of high infliximab trough levels in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 940-946.	0.6	38